ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.5 | 2.8 | 1.5 |
| Other income | 6.8 | 2.8 | 1.2 |
| Total income | 8.3 | 5.6 | 2.7 |
| Profit before exceptional items & tax | -45.6 | -101.9 | -43.9 |
| Profit before tax | -45.6 | -101.9 | -43.9 |
| Net profit | -45.6 | -101.9 | -43.9 |
| Operating margin | -549.4% | n/m | n/m |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +0.00% |
|---|
NSE results filing, NSE: SUVEN. Figures extracted from the filing.
Suven Life Sciences Ltd: key numbers
- Share price
- ₹280.00
- Market cap
- ₹7,912 Cr
- Revenue (annual)
- ₹7.11 Cr
- Net profit (annual)
- ₹-276.3 Cr
- P/E (TTM)
- -20.7×Sector 54.5×
- Promoter holding
- 65.47%-4.61% QoQ
- FII holding
- 0.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suven Life Sciences Ltd
All →Suven Life Sciences Business Update
Suven Life Sciences will present seven posters on its CNS pipeline at Neuroscience 2026, Washington DC. Presentations span Phase-3 and preclinical candidates targeting neurodegenerative and neuropsychiatric disorders.
Suven Life Sciences Preferential Issue
Suven's monitoring agency report covers its Rs 857.64 Crore preferential warrant proceeds for the quarter ended September 2026. Shareholders approved reallocation of objects on August 25, 2026.
- Value
- ₹857.6 Cr
Suven Life Sciences Q2 FY27 Results: Net Loss of ₹106.9 Cr, Loss Widens
Suven Life Sciences Ltd reported revenue from operations of ₹1.2 Cr (+33.3% YoY) and a net loss of ₹106.9 Cr for Q2 FY27.
- Key figure
- Net loss ₹106.9 Cr
Suven Life Sciences Board Meeting Date
Suven Life Sciences scheduled its board meeting for 5 November 2026 to approve Q1 and H1 FY27 unaudited results. The trading window closed from 1 October 2026 until 48 hours post-declaration.
Suven Life Sciences Other Announcement
Suven Life Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI regulations.
Suven Life Sciences Business Update
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
- clinical trial enrollment
- 424.0 patients